| pubmed-article:9352310 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9352310 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:9352310 | lifeskim:mentions | umls-concept:C0027950 | lld:lifeskim |
| pubmed-article:9352310 | lifeskim:mentions | umls-concept:C0014806 | lld:lifeskim |
| pubmed-article:9352310 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:9352310 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:9352310 | pubmed:dateCreated | 1998-1-8 | lld:pubmed |
| pubmed-article:9352310 | pubmed:abstractText | 1. Erythromycin (2-100 micrograms ml-1) produced a concentration-related inhibition of superoxide generation and elastase release induced by in vitro exposure of human polymorphonuclear leukocytes (PMNs) to the chemotactic peptide N-formylmethionyl-leucyl-phenylalanine (FMLP; 30 nM). 2. By contrast, erythromycin (100 micrograms ml-1) did not alter the leukotriene B4 production elicited by FMLP (30 nM; in the presence of thimerosal 20 microM) or the intracellular calcium changes promoted by FMLP (30 nM; in the absence or presence of thimerosal 20 microM). 3. These results indicate that by reducing chemoattractant-triggered release of oxidative and proteolytic mediators from human PMNs, erythromycin may have clinically useful antiinflammatory effects. | lld:pubmed |
| pubmed-article:9352310 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9352310 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9352310 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9352310 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9352310 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9352310 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9352310 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9352310 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9352310 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9352310 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9352310 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9352310 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9352310 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9352310 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:9352310 | pubmed:issn | 0306-3623 | lld:pubmed |
| pubmed-article:9352310 | pubmed:author | pubmed-author:BerteFF | lld:pubmed |
| pubmed-article:9352310 | pubmed:author | pubmed-author:SanzCC | lld:pubmed |
| pubmed-article:9352310 | pubmed:author | pubmed-author:MorcilloE JEJ | lld:pubmed |
| pubmed-article:9352310 | pubmed:author | pubmed-author:CortijoJJ | lld:pubmed |
| pubmed-article:9352310 | pubmed:author | pubmed-author:VillagrasaVV | lld:pubmed |
| pubmed-article:9352310 | pubmed:author | pubmed-author:PerpinaMM | lld:pubmed |
| pubmed-article:9352310 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9352310 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:9352310 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9352310 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9352310 | pubmed:pagination | 605-9 | lld:pubmed |
| pubmed-article:9352310 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:9352310 | pubmed:meshHeading | pubmed-meshheading:9352310-... | lld:pubmed |
| pubmed-article:9352310 | pubmed:meshHeading | pubmed-meshheading:9352310-... | lld:pubmed |
| pubmed-article:9352310 | pubmed:meshHeading | pubmed-meshheading:9352310-... | lld:pubmed |
| pubmed-article:9352310 | pubmed:meshHeading | pubmed-meshheading:9352310-... | lld:pubmed |
| pubmed-article:9352310 | pubmed:meshHeading | pubmed-meshheading:9352310-... | lld:pubmed |
| pubmed-article:9352310 | pubmed:meshHeading | pubmed-meshheading:9352310-... | lld:pubmed |
| pubmed-article:9352310 | pubmed:meshHeading | pubmed-meshheading:9352310-... | lld:pubmed |
| pubmed-article:9352310 | pubmed:meshHeading | pubmed-meshheading:9352310-... | lld:pubmed |
| pubmed-article:9352310 | pubmed:meshHeading | pubmed-meshheading:9352310-... | lld:pubmed |
| pubmed-article:9352310 | pubmed:meshHeading | pubmed-meshheading:9352310-... | lld:pubmed |
| pubmed-article:9352310 | pubmed:meshHeading | pubmed-meshheading:9352310-... | lld:pubmed |
| pubmed-article:9352310 | pubmed:meshHeading | pubmed-meshheading:9352310-... | lld:pubmed |
| pubmed-article:9352310 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9352310 | pubmed:articleTitle | Effects of erythromycin on chemoattractant-activated human polymorphonuclear leukocytes. | lld:pubmed |
| pubmed-article:9352310 | pubmed:affiliation | Department of Pharmacology, College of Medicine and Dentistry, Valencia University, Spain. | lld:pubmed |
| pubmed-article:9352310 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9352310 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:9352310 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9352310 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9352310 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9352310 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9352310 | lld:pubmed |
